国产创新药书写"价值医疗"新篇 根据《中国卒中学会急性缺血性卒中再灌注治疗指南2024》，我国每年约有300万卒中新发病例，其中缺血性卒中约占80%。 目前我国缺血性脑卒中发病率和死亡率仍呈现上升趋势，卒中已成为国内成人致死、致残的首位病因，也是医保支付的重要疾 病，带来巨大的社会负担。 但卒中防控仍存三大痛点——公众认知不足、防治体系需完善、基层能力薄弱。早期识别率不足三成，急救黄金时间常被浪 费，溶栓取栓技术普及率低，健康素养亟待提升。 普佑克作为我国自主研发的第三代溶栓药物，精准破解了这一行业痛点。其通过独特的纤溶酶原靶向激活机制，在实现高效血 管再通的同时显著降低出血风险。 近期，国际顶级医疗期刊《JAMA》和《柳叶刀-神经病学》相继发表研究成果，显示接受重组人尿激酶原(普佑克)溶栓患者，较 对照组在效果一致的前提下，呈现出更低的脑出血发生率(PROST-2研究)，且7天内溶栓相关的大出血和全身系统性出血事件发 生率也都显著低于对照组。 天士力研发中心负责人指出，作为新一代溶栓药物，普佑克的核心优势源于独特的分子结构与作用机制。普佑克的活性成分为 重组人尿激酶原，功能及安全性与人体天然分泌的尿激酶原最 ...

2025 年 11 月 10 日 行业研究 医疗器械和医疗服务板块收入表现靓丽，化学制剂板块净利润同比增长 ——医药生物行业跨市场周报（20251109） 要点 行情回顾：上周，医药生物指数下跌 2.40%，跑输沪深 300 指数 3.22pp，在 31 个子行业中排名第 29。港股恒生医疗健康指数上周收跌 2.62%，跑输恒生国企 指数 3.7pp。 本周观点：医疗器械和医疗服务板块收入表现靓丽，化学制剂板块净利润同比增 长。 25 年前三季度医药生物板块实现收入 18257.4 亿元（YOY-1.97%），实现归母 净 利 润 1396.6 亿 元 （ YOY-1.59% ） ； 单 三 季 度 实 现 收 入 5985.4 亿 元 （YOY+0.78%），实现归母净利润 405.1 亿元（YOY+7.67%）。从毛利表现来 看，25 年前三季度医药板块实现销售毛利润 5734.5 亿元（YOY-6.1%），对应 整体毛利率为 31.4%（YOY-1.4pct）。从各医药申万二级行业表现来看，25Q3 各板块继续分化，医疗器械和医疗服务板块收入表现靓丽，化学制剂板块净利润 继续同比增长，其他细分子板块表现 ...

Core Insights - Tianjin Shili Group announced the launch of a health and wellness tourism strategy upgrade during the "2026 National Taiwan Quality Commitment Conference and National Taiwan Digital Collection Wine Sealing Ceremony" held in Renhuai, Guizhou [1] Strategic Initiatives - The company outlined a health and wellness tourism strategy path led by "wine and tourism integration," emphasizing the dual commitment to traditional craftsmanship and digital transformation [3] - The strategy includes the promotion of a "tea and tourism integration" plan through its subsidiary, Di Bo Er Pu'er Tea, focusing on hotels, resorts, and comprehensive tourism complexes [3] Ecosystem Development - The strategic initiative will leverage a partnership with Guizhou Tianyue Tourism Group, which has been operational since April 2017 and has received over 500,000 tourists annually, ranking among the top 20 travel agency brands in China by 2025 [3] - This marks a significant transformation for Tianjin Shili Group from a health product manufacturer to an integrated operation platform combining "products + services + scenarios" [3]

Core Insights - The company is launching a strategic upgrade in the health and wellness tourism sector, appointing Wang Qunfu as CEO of the new division [1][5] - The strategy emphasizes the integration of traditional liquor production with digital upgrades and immersive cultural experiences [3][5] Strategic Initiatives - The health and wellness tourism strategy is centered around "liquor and tourism integration," aiming to create a seamless value chain from production to experiential tourism [3] - The company plans to enhance its offerings by developing immersive cultural experiences related to its liquor products [3] Ecological Layout - The company will also promote a "tea and tourism integration" plan through its subsidiary, focusing on hotels, resorts, and comprehensive tourism complexes [4] - A strategic partnership with Guizhou Tianyue Tourism Group will leverage their resources to enhance channel integration and cultural exploration [4] Transformation Goals - The strategic upgrade signifies a shift from being a health product manufacturer to an integrated platform combining products, services, and experiences [5] - The company aims to extend traditional health consumer products into a composite ecosystem that merges tourism experiences with cultural dissemination [5]

Core Viewpoint - Tian Shi Li (600535.SH) reported a decline in third-quarter revenue but an increase in net profit attributable to shareholders, indicating mixed financial performance for the company in 2025 [1][2]. Financial Performance Summary - The company's third-quarter revenue was 2.022 billion yuan, a year-on-year decrease of 3.27% [1][2]. - Net profit attributable to shareholders was 210 million yuan, reflecting a year-on-year increase of 16.56% [1][2]. - Net profit excluding non-recurring gains and losses was 189 million yuan, showing a year-on-year decline of 23.64% [1][2]. - For the first three quarters of 2025, total revenue was 6.311 billion yuan, down 2.35% year-on-year [2]. - Net profit attributable to shareholders for the first three quarters was 984 million yuan, up 16.88% year-on-year [2]. - Net profit excluding non-recurring gains and losses for the first three quarters was 829 million yuan, down 15.59% year-on-year [2]. - The net cash flow from operating activities was 873 million yuan, a decrease of 26.67% year-on-year [2]. Shareholding Structure Changes - Tian Shi Li's controlling shareholder changed from Tian Shi Li Biological Pharmaceutical Industry Group to China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. after a share transfer [3][4]. - Following the transfer, Tian Shi Li Group and its concerted parties held 261,452,489 shares, representing 17.50% of the total share capital [3][4]. - China Resources Sanjiu directly holds 418,306,002 shares, accounting for 28% of the total share capital [3][4]. - The total transfer price for the shares was approximately 6.21 billion yuan [4].

Core Viewpoint - Tianjin Tasly Pharmaceutical Group Co., Ltd. reported a decline in revenue for Q3 2025, while net profit showed growth, indicating mixed financial performance [1] Financial Performance - In Q3 2025, the company achieved revenue of 2.022 billion yuan, a year-on-year decrease of 3.27% [1] - The net profit attributable to shareholders for Q3 2025 was 210 million yuan, reflecting a year-on-year increase of 16.56% [1] - For the first three quarters of 2025, total revenue reached 6.311 billion yuan, down 2.35% compared to the same period last year [1] - The net profit attributable to shareholders for the first three quarters was 984 million yuan, which is a year-on-year increase of 16.88% [1] Revenue Breakdown - The revenue from the pharmaceutical manufacturing segment decreased by 0.47% year-on-year [1] - The revenue from the pharmaceutical commerce segment saw a significant decline of 16.70% year-on-year [1]

Market Overview - The Chinese traditional medicine sector experienced a decline of 0.31% on October 27, with Zhenbaodao leading the drop [1] - The Shanghai Composite Index closed at 3996.94, up 1.18%, while the Shenzhen Component Index closed at 13489.4, up 1.51% [1] Stock Performance - Notable gainers in the traditional medicine sector included: - Weikang Pharmaceutical (300878) with a closing price of 23.90, up 3.46% [1] - ST Xiangxue (300147) at 10.25, up 2.60% [1] - Jiuzi Tang (000989) at 10.02, up 2.14% [1] - Conversely, Zhenbaodao (603567) saw a significant decline of 6.23%, closing at 11.13 [2] - Other notable decliners included: - Taiji Group (600129) down 3.21% [2] - Kunming Pharmaceutical Group (600422) down 2.21% [2] Capital Flow - The traditional medicine sector experienced a net outflow of 344 million yuan from institutional investors, while retail investors saw a net inflow of 181 million yuan [2] - The sector's overall capital flow indicated a mixed sentiment, with speculative funds showing a net inflow of 163 million yuan [2] Individual Stock Capital Flow - Key stocks with significant capital flow included: - Jilin Aodong (000623) with a net inflow of 81.97 million yuan from institutional investors [3] - Yunnan Baiyao (000538) with a net inflow of 62.26 million yuan [3] - Jiuzi Tang (000989) with a net inflow of 26.22 million yuan [3] - Notable outflows were observed in: - Jilin Aodong with a retail net outflow of 72.25 million yuan [3] - Yunnan Baiyao with a retail net outflow of 67.54 million yuan [3]

Core Viewpoint - Zhejiang Merchants Securities report indicates that Tianjin Tasly Pharmaceutical achieved a net profit attributable to shareholders of 984 million yuan in the first three quarters, representing a year-on-year increase of 16.88% [1] - In Q3 alone, the net profit attributable to shareholders was 210 million yuan, also reflecting a year-on-year growth of 16.56% [1] - The performance aligns with expectations, and there is optimism regarding the empowerment from Sanjiu [1] Financial Performance - The net profit for the first three quarters reached 984 million yuan, marking a 16.88% increase compared to the previous year [1] - The Q3 net profit was recorded at 210 million yuan, showing a 16.56% year-on-year growth [1]

Summary of Tianjin Tasly Pharmaceutical Conference Call Company Overview - **Company**: Tianjin Tasly Pharmaceutical Co., Ltd. - **Industry**: Pharmaceutical Industry in China Key Points and Arguments Integration with China Resources Sanjiu - The integration with China Resources Sanjiu has progressed smoothly, achieving the 100-day integration goal and entering the first year of integration phase [2][6] - Focus areas include stabilizing business, teams, and customers while promoting synergy and empowerment [2][6] - The vision is to become a leading enterprise in the Chinese pharmaceutical market through innovation-driven strategies [6] Financial Performance - For the first three quarters of 2025, the company reported revenue of 6.31 billion yuan and a net profit of 984 million yuan [4] - Pharmaceutical industrial sales remained stable at 5.709 billion yuan, with cardiovascular and metabolic segments showing a slight growth of 1.16% [4] - The collaboration with China Resources Sanjiu has led to a 20% increase in terminal coverage in lower-tier cities [4][12] Product Development and Market Opportunities - Core products like Compound Danshen Dripping Pills are seeing steady sales growth, with expectations to reach 250 to 300 million yuan this year, nearly doubling year-on-year [4][16] - The newly approved indication for the drug Puyouke for cerebral infarction is expected to enter the national medical insurance negotiation directory next year, with significant growth anticipated by 2026-2027 [2][8] - The market potential for cerebral infarction treatment is substantial, with 4.5 to 5.5 million new cases annually and a low treatment rate of around 5% [8] R&D Strategies - The company emphasizes innovation in drug development, focusing on cardiovascular, neurological, and digestive fields [9][10] - Plans to enhance the pipeline of innovative traditional Chinese medicine (TCM) and strengthen existing projects [11] - The company is developing advanced therapeutic drugs, particularly in cell and gene therapy (CGT) and small nucleic acid products [11] Clinical Trials and New Products - The PD-L1/VGF dual antibody project has shown promising results in Phase I trials, with Phase II studies underway [13][14] - The FGF21 analog project has demonstrated good safety and efficacy in improving glucose and lipid metabolism [15] - New antidepressant GS1,101 has completed Phase II trials and is expected to become a significant innovative treatment option [17][18] Market Trends and Future Outlook - The company aims to leverage national policy opportunities to drive growth in county-level medical community drug directories [2][7] - Plans to expand retail channels and integrate online sales resources to build a healthy consumption ecosystem [8][12] - The company is actively pursuing inclusion in the national basic medical insurance directory for more proprietary products [20] Potential Products in Clinical Trials - Several innovative TCM products are in Phase III clinical trials, including those targeting common ailments like colds and acute gout [19] - The company is also exploring treatments for conditions like acute ischemic stroke and chronic heart failure through stem cell therapies [21] Additional Important Information - The company is implementing a 6S management system to enhance operational efficiency [6] - The integration with China Resources Sanjiu is expected to strengthen the company's market position and operational capabilities [12]

Core Insights - Tianjin Tasly Pharmaceutical Group Co., Ltd. reported a revenue of 6.31 billion yuan for the first three quarters of 2025, a year-on-year decrease of 2.4% [1] - The net profit attributable to shareholders was 984 million yuan, an increase of 16.9% year-on-year [1] - The company's operating cash flow net amount was 873 million yuan, down 26.7% year-on-year [1] Financial Performance - In Q3 2025, the company achieved a revenue of 2.02 billion yuan, a decline of 3.3% year-on-year [1] - The net profit for Q3 was 210 million yuan, up 16.6% year-on-year [1] - The non-recurring net profit for Q3 was 189 million yuan, down 23.6% year-on-year [1] Business Segments - The pharmaceutical industrial segment generated a revenue of 5.709 billion yuan, a slight decrease of 0.47% compared to the same period in 2024 [1] - The pharmaceutical commercial segment reported a revenue of 565 million yuan, a significant decline of 16.7% year-on-year [2] - The overall gross margin for the pharmaceutical industrial segment decreased from 71.14% in 2024 to 70.56% in 2025 [1] Cost Analysis - The main business cost for the pharmaceutical industrial segment was 1.681 billion yuan, an increase of 1.52% year-on-year [1] - The pharmaceutical commercial segment's main business cost was 390 million yuan, down 16.81% year-on-year [2] - The overall gross margin for the company improved slightly from 66.89% in 2024 to 67.00% in 2025 despite revenue decline [2] Sector Performance - In the cardiovascular and metabolic field, revenue reached 3.186 billion yuan, a growth of 1.16% year-on-year [2] - The gross margin in this sector decreased from 78.68% to 77.57% due to rising costs [2] - The neuro/psychiatric field saw a revenue of 1.085 billion yuan, down 6.48% year-on-year, with a gross margin decline from 50.57% to 49.44% [3]